Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

Shares of Lipocine stock opened at $3.28 on Friday. The stock has a market cap of $17.55 million, a PE ratio of -4.32 and a beta of 1.42. The firm has a fifty day moving average price of $3.68 and a 200 day moving average price of $4.52. Lipocine has a 1 year low of $2.91 and a 1 year high of $11.79.

Institutional Trading of Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC lifted its holdings in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the period. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 as of its most recent filing with the Securities and Exchange Commission. 9.11% of the stock is currently owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.